Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 3, 2011, Pages 324-332

  Lei, Tingjun ^a   Srinivasan, Supriya ^a   Tang, Yuan ^a   Manchanda, Romila ^a   Nagesetti, Abhignyan ^a   Fernandez Fernandez, Alicia ^a   McGoron, Anthony J ^a  

^a The Department of Electrical and Computer Engineering   (United States)

Author keywords

Apoptosis; Cytotoxicity; Doxorubicin; HER 2 antibody; P glycoprotein; PLGA

Indexed keywords

APOPTOSIS; DOXORUBICIN; HER-2 ANTIBODY; P-GLYCOPROTEIN; PLGA;

ANTIBODIES; CELL CULTURE; CELL DEATH; DISEASES; DRUG DELIVERY; GLYCOPROTEINS; ORGANIC POLYMERS;

CYTOTOXICITY;

DOXORUBICIN; NANOPARTICLE; POLYGLACTIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; LIGHT SCATTERING; NANOENCAPSULATION; OVARY CANCER; PARTICLE SIZE; TREATMENT OUTCOME; UTERUS CANCER; ZETA POTENTIAL;

ANTIBODIES; BIOLOGICAL TRANSPORT; CELL DEATH; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; INTRACELLULAR SPACE; KINETICS; LIGHT; MICROSCOPY, CONFOCAL; NANOPARTICLES; PARTICLE SIZE; SCATTERING, RADIATION; STATIC ELECTRICITY; SUBCELLULAR FRACTIONS;

EID: 79956337181     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2010.11.004     Document Type: Article

References (49)

1. Vermorken J.B. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer 2003, 13(Suppl 2):178-184.
2. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
3. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
4. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54:631-651.
5. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
6. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95:4607-4612.
7. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
8. Sapra P., Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003, 42:439-462.
9. Vasir J.K., Reddy M.K., Labhasetwar V. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005, 1:47-64.
10. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
11. Garnett M.C. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 2001, 53:171-216.
12. Funaro A., Horenstein A.L., Santoro P., Cinti C., Gregorini A., Malavasi F. Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 2000, 18:385-401.
13. Nobs L., Buchegger F., Gurny R., Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 2004, 93:1980-1992.
14. Jaracz S., Chen J., Kuznetsova L.V., Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005, 13:5043-5054.
15. Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 2005, 26:5898-5906.
16. Astete C.E., Sabliov C.M. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006, 17:247-289.
17. Danhier F., Lecouturier N., Vroman B., Jerome C., Marchand-Brynaert J., Feron O., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009, 133:11-17.
18. Yoo H.S., Oh J.E., Lee K.H., Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 1999, 16:1114-1118.
19. Yoo H.S., Park T.G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001, 70:63-70.
20. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005, 103:405-418.
21. Liu J.R., Opipari A.W., Tan L., Jiang Y., Zhang Y., Tang H., et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002, 62:924-931.
22. Wolf B.B., Schuler M., Li W., Eggers-Sedlet B., Lee W., Tailor P., et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 2001, 276:34244-34251.
23. Yang J., Lee C.H., Park J., Seo S., Lim E.K., Song Y.J., et al. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 2007, 17:2695-2699.
24. Manchanda R., Fernandez-Fernandez A., Nagesetti A., Mcgoron A.J. Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. Colloids Surf B Biointerfaces 2010, 75:260-267.
25. Misra R., Sahoo S.K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 2010, 39:152-163.
26. Mo Y., Lim L.Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release 2005, 107:30-42.
27. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor-cell lines. J Natl Cancer Inst 1991, 83:757-766.
28. Tang Y., Mcgoron A.J. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B 2009, 97:138-144.
29. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002, 82:105-114.
30. Redhead H.M., Davis S.S., Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release 2001, 70:353-363.
31. Barnes T.J., Prestidge C.A. PEO-PPO-PEO block copolymers at the emulsion droplet-water interface. Langmuir 2000, 16:4116-4121.
32. Stolnik S., Dunn S.E., Garnett M.C., Davies M.C., Coombes A.G., Taylor D.C., et al. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 1994, 11:1800-1808.
33. Sun B., Ranganathan B., Feng S.S. Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008, 29:475-486.
34. Chittasupho C., Xie S.X., Baoum A., Yakovleva T., Siahaan T.J., Berkland C.J. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009, 37:141-150.
35. Tewes F., Munnier E., Antoon B., Ngaboni-Okassa L., Cohen-Jonathan S., Marchais H., et al. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm 2007, 66:488-492.
36. Stevanovic M., Maksin T., Petkovic J., Filipic M., Uskokovic D. An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly(d,l-lactide-co-glycolide) nanospheres. Nanotechnology 2009, 20:335102.
37. Arifin D.Y., Lee L.Y., Wang C.H. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems. Adv Drug Deliv Rev 2006, 58:1274-1325.
38. Panyam J., Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 2004, 1:77-84.
39. Qaddoumi M.G., Gukasyan H.J., Davda J., Labhasetwar V., Kim K.J., Lee V.H. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol Vis 2003, 9:559-568.
40. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 2002, 277:18021-18028.
41. Belloc F., Lacombe F., Dumain P., Lopez F., Bernard P., Boisseau M.R., et al. Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. Cytometry 1992, 13:880-885.
42. Cartiera M.S., Johnson K.M., Rajendran V., Caplan M.J., Saltzman W.M. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 2009, 30:2790-2798.
43. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(d,l-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002, 16:1217-1226.
44. Miraglia E., Viarisio D., Riganti C., Costamagna C., Ghigo D., Bosia A. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 2005, 115:924-929.
45. Gong Y., Duvvuri M., Krise J.P. Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 2003, 278:50234-50239.
46. Duvvuri M., Krise J.P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 2005, 10:1499-1509.
47. Yang R., Shim W.S., Cui F.D., Cheng G., Han X., Jin Q.R., et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 2009, 371:142-147.
48. Tang Y., Lei T., Manchanda R., Nagesetti A., Fernandez-Fernandez A., Srinivasan S., et al. Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm Res 2010, 27:2242-2253.
49. Manchanda R., Lei T., Tang Y., Fernandez-Fernandez A., Mcgoron A.J. Cellular uptake and cytotoxicity of a novel ICG-DOX-PLGA dual agent polymer nanoparticle delivery system. IFMBE Proc 2010, 32:228-231.